These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 27454199)

  • 1. Risk selection and heterogeneous preferences in health insurance markets with a public option.
    Polyakova M
    J Health Econ; 2016 Sep; 49():153-68. PubMed ID: 27454199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A model to decompose the performance of supplementary private health insurance markets.
    Leidl R
    Int J Health Care Finance Econ; 2008 Sep; 8(3):193-208. PubMed ID: 18568435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guaranteed renewability and the problem of risk variation in individual health insurance markets.
    Patel V; Pauly MV
    Health Aff (Millwood); 2002; Suppl Web Exclusives():W280-9. PubMed ID: 12703584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Public and private health insurance in Germany: the ignored risk selection problem.
    Grunow M; Nuscheler R
    Health Econ; 2014 Jun; 23(6):670-87. PubMed ID: 23696240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How can the regulator show evidence of (no) risk selection in health insurance markets? Conceptual framework and empirical evidence.
    van de Ven WP; van Vliet RC; van Kleef RC
    Eur J Health Econ; 2017 Mar; 18(2):167-180. PubMed ID: 26837411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Public option and private profits: what do markets expect?
    Milani F
    Appl Health Econ Health Policy; 2010; 8(3):155-65. PubMed ID: 20201607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk selection and risk adjustment: improving insurance in the individual and small group markets.
    Baicker K; Dow WH
    Inquiry; 2009; 46(2):215-28. PubMed ID: 19694394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Financial incentives and patient selection: Hospital physicians' views on cream skimming and economic management focus in Norway.
    Kjøstolfsen GH; Baheerathan J; Martinussen PE; Magnussen J
    Health Policy; 2021 Jan; 125(1):98-103. PubMed ID: 33208250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk Selection under Public Health Insurance with Opt-Out.
    Panthöfer S
    Health Econ; 2016 Sep; 25(9):1163-81. PubMed ID: 27237082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Private health insurance in Germany and Chile: two stories of co-existence, segmentation and conflict.
    Roman-Urrestarazu A; Yang JC; Ettelt S; Thalmann I; Seguel Ravest V; Brayne C
    Int J Equity Health; 2018 Aug; 17(1):112. PubMed ID: 30075777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ignoring small predictable profits and losses: a new approach for measuring incentives for cream skimming.
    van Barneveld EM; Lamers LM; van Vliet RC; van de Ven WP
    Health Care Manag Sci; 2000 Feb; 3(2):131-40. PubMed ID: 10780281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cream-skimming in deregulated social health insurance: evidence from Switzerland.
    Beck K; Zweifel P
    Dev Health Econ Public Policy; 1998; 6():211-27. PubMed ID: 10662405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing risk selection incentives in health sector reforms.
    Puig-Junoy J
    Int J Health Plann Manage; 1999; 14(4):287-311. PubMed ID: 11184915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asymmetric Information in Iranian's Health Insurance Market: Testing of Adverse Selection and Moral Hazard.
    Lotfi F; Abolghasem Gorji H; Mahdavi G; Hadian M
    Glob J Health Sci; 2015 Apr; 7(6):146-55. PubMed ID: 26153155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are Colombian sickness funds cream skimming enrollees? An analysis with suggestions for policy improvement.
    Trujillo AJ; McCalla DC
    J Policy Anal Manage; 2004 Aug; 23(4):873-88. PubMed ID: 15499708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lifetime cover in private insurance markets.
    Brown HS; Connelly LB
    Int J Health Care Finance Econ; 2005 Mar; 5(1):75-88. PubMed ID: 15714264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spillover effects of supplementary on basic health insurance: evidence from The Netherlands.
    Roos AF; Schut FT
    Eur J Health Econ; 2012 Feb; 13(1):51-62. PubMed ID: 20862510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Self-selection and moral hazard in Chilean health insurance.
    Sapelli C; Vial B
    J Health Econ; 2003 May; 22(3):459-76. PubMed ID: 12683962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple choice health insurance: the lessons and challenge to private insurers.
    Jones SB
    Inquiry; 1990; 27(2):161-6. PubMed ID: 2142134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insurability and the HIV epidemic: ethical issues in underwriting.
    Daniels N
    Milbank Q; 1990; 68(4):497-525. PubMed ID: 2292989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.